Skip to main content
AAN.com

Abstract

Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (wingerchuk.pdf)

References

1.
Multiple Sclerosis Clinical Practice Guidelines: Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans Association, 1998.
2.
Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000;4:1–61.
3.
Wingerchuk DM, Benarroch E, Rodriguez M. Aspirin for multiple sclerosis related fatigue. Can J Neurol Sci 1997;24:161.
4.
Senn, S. Cross-over trials in clinical research. West Sussex, England: John Wiley and Sons Ltd., 1993.
5.
Wingerchuk DM, Noseworthy JH, Weinshenker BG. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin Proc 1997;72:1070–1079.
6.
Amin AR, Attur MG, Pillinger M, Abramson SB. The pleiotropic functions of aspirin: mechanisms of action. Cell Mol Life Sci 1999;56:305–312.
7.
Conti B, Tabarean I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci 2004;9:1433–1449.
8.
Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183–1187.
9.
Schwid SR, Thornton CA, Pandya S, et al. Quantitative assessment of motor fatigue and strength in MS. Neurology 1999;53:743–750.
10.
Krupp LB, Elkins LE. Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology 2000;55:934–939.

Information & Authors

Information

Published In

Neurology®
Volume 64Number 7April 12, 2005
Pages: 1267-1269
PubMed: 15824361

Publication History

Published online: April 11, 2005
Published in print: April 12, 2005

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

D. M. Wingerchuk, MD, FRCPC
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
E. E. Benarroch, MD
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
P. C. O’Brien, PhD
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
B. M. Keegan, MD, FRCPC
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
C. F. Lucchinetti, MD
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
J. H. Noseworthy, MD, FRCPC
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
B. G. Weinshenker, MD, FRCPC
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
M. Rodriguez, MD
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.

Notes

Address correspondence and reprint requests to Dr. Dean M. Wingerchuk, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259; e-mail [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Assessment of acupuncture's effectiveness in mitigating fatigue among patients afflicted with multiple sclerosis: A systematic review and meta-analysis, Complementary Therapies in Clinical Practice, 57, (101902), (2024).https://doi.org/10.1016/j.ctcp.2024.101902
    Crossref
  2. A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis, Journal of Neurology, 271, 5, (2207-2215), (2024).https://doi.org/10.1007/s00415-023-12147-6
    Crossref
  3. The neuroimmunology of fatigue in multiple sclerosis, Translational Neuroimmunology, Volume 8, (55-72), (2023).https://doi.org/10.1016/B978-0-443-18578-6.00004-0
    Crossref
  4. Multiple sclerosis-related fatigue lacks a unified definition, Journal of Research in Medical Sciences, 27, 1, (24), (2022).https://doi.org/10.4103/jrms.jrms_1401_20
    Crossref
  5. A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis, CNS & Neurological Disorders - Drug Targets, 21, 2, (160-187), (2022).https://doi.org/10.2174/1871527319666200825164123
    Crossref
  6. Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment, Radiology, 303, 3, (486-497), (2022).https://doi.org/10.1148/radiol.211252
    Crossref
  7. Literatur, Multiple Sklerose, (468-512), (2022).https://doi.org/10.1016/B978-3-437-22085-2.00028-8
    Crossref
  8. Drug Treatment of Psychiatric Symptoms Occurring in the Context of Other Disorders, The Maudsley Prescribing Guidelines in Psychiatry, (777-830), (2021).https://doi.org/10.1002/9781119870203.mpg010
    Crossref
  9. Efficacy and Safety of Amantadine for the Treatment of Fatigue in Multiple Sclerosis: A Systematic Review and meta-analysis, Neurodegenerative Disease Management, 10, 6, (383-395), (2020).https://doi.org/10.2217/nmt-2020-0030
    Crossref
  10. ASPIRE trial: study protocol for a double-blind randomised controlled trial of aspirin for overheating during exercise in multiple sclerosis, BMJ Open, 10, 11, (e039691), (2020).https://doi.org/10.1136/bmjopen-2020-039691
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share